Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Fluvoxamine Action Pathway (New)
Homo sapiens
Drug Action Pathway
Fluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occasion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
It's mechanism of action it to bind selectively bind to the sodium dependent serotonin transporter and blocking the recycling of serotonin from the synapse. As serotonin accumulates it enhances the serotonergic function of the 5-hydroxytryptamine 1A receptor leading to decreased anxiety and depressive moods.
References
Fluvoxamine Pathway (New) References
Yohn C. N, Gergues M. M, Samuels B. A. The role of 5-HT receptors in depression. Mol Brain 10: 28, 2017.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings